Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B H Wolffenbuttel

Showing results (1-10 of 96) with videos related to

Pageof 10
Sort By:
The Netherlands Journal of Medicine|December 1, 1993
The DCCT: "metabolic control matters". Diabetes Control and Complications TrialB H Wolffenbuttel
The Netherlands Journal of Medicine|December 11, 1999
Repaglinide--a new compound for the treatment of patients with type 2 diabetesB H Wolffenbuttel
The Netherlands Journal of Medicine|October 1, 1993
Type 2 diabetes mellitus. Aspects of complications and treatmentB H Wolffenbuttel
Diabetes Research (Edinburgh, Scotland)|October 1, 1988
Insulin therapy does not diminish beta-cell damage in the neonatal streptozotocin-injected ratB H Wolffenbuttel, J Vreeburg
Diabetes Care|March 31, 1999
A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study GroupB H Wolffenbuttel, R Landgraf
Nederlands Tijdschrift Voor Geneeskunde|June 22, 1996
[Long-term complications in diabetes mellitus: role of irreversible glycosylation products]M Treskes, B H Wolffenbuttel
Postgraduate Medical Journal|November 1, 1996
New treatments for patients with type 2 diabetes mellitusB H Wolffenbuttel, M B Graal
Drugs & Aging|January 21, 2000
The use of sulphonylureas in the elderlyM B Graal, B H Wolffenbuttel
The Netherlands Journal of Medicine|April 1, 1993
Low cholesterol and excess mortality: a real relationship?W A Oranje, B H Wolffenbuttel
The Netherlands Journal of Medicine|June 1, 1993
Aminoguanidine, a potential drug for the treatment of diabetic complicationsB H Wolffenbuttel, M S Huijberts
Pageof 10

Showing results (1-10 of 96) with videos related to

Sort By:
Pageof 10
The Netherlands Journal of Medicine|December 1, 1993
The DCCT: "metabolic control matters". Diabetes Control and Complications TrialB H Wolffenbuttel
The Netherlands Journal of Medicine|December 11, 1999
Repaglinide--a new compound for the treatment of patients with type 2 diabetesB H Wolffenbuttel
The Netherlands Journal of Medicine|October 1, 1993
Type 2 diabetes mellitus. Aspects of complications and treatmentB H Wolffenbuttel
Diabetes Research (Edinburgh, Scotland)|October 1, 1988
Insulin therapy does not diminish beta-cell damage in the neonatal streptozotocin-injected ratB H Wolffenbuttel, J Vreeburg
Diabetes Care|March 31, 1999
A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study GroupB H Wolffenbuttel, R Landgraf
Nederlands Tijdschrift Voor Geneeskunde|June 22, 1996
[Long-term complications in diabetes mellitus: role of irreversible glycosylation products]M Treskes, B H Wolffenbuttel
Postgraduate Medical Journal|November 1, 1996
New treatments for patients with type 2 diabetes mellitusB H Wolffenbuttel, M B Graal
Drugs & Aging|January 21, 2000
The use of sulphonylureas in the elderlyM B Graal, B H Wolffenbuttel
The Netherlands Journal of Medicine|April 1, 1993
Low cholesterol and excess mortality: a real relationship?W A Oranje, B H Wolffenbuttel
The Netherlands Journal of Medicine|June 1, 1993
Aminoguanidine, a potential drug for the treatment of diabetic complicationsB H Wolffenbuttel, M S Huijberts
Pageof 10